Literature DB >> 34070352

Oncological Frontiers in the Treatment of Malignant Pleural Mesothelioma.

Emanuele Vita1,2, Alessio Stefani1,2, Mariantonietta Di Salvatore1,2, Marco Chiappetta3, Filippo Lococo3, Stefano Margaritora3, Giampaolo Tortora1,2, Emilio Bria1,2.   

Abstract

Malignant pleural mesothelioma (MPM) is a rare malignancy characterized by very poor prognosis and lack of treatment options. Immunotherapy has rapidly emerged as an effective tool for MPM, particularly for tumors of non-epithelioid histology. At the same time, comprehensive genomic sequencing may open the way to new-generation targeted-drugs able to hit specific MPM molecular vulnerabilities. These innovations will possibly enrich, but also dramatically complicate, the elucidation of treatment algorithms. Multidisciplinary integration is urgently needed.

Entities:  

Keywords:  immunotherapy; malignant pleural mesothelioma; target therapy

Year:  2021        PMID： 34070352     DOI： 10.3390/jcm10112290

Source DB:  PubMed          Journal:  J Clin Med        ISSN： 2077-0383            Impact factor:   4.241


  58 in total

1.  Inhibition of Hsp90 leads to cell cycle arrest and apoptosis in human malignant pleural mesothelioma.

Authors:  Junichi Okamoto; Iwao Mikami; Yuichi Tominaga; Kristopher M Kuchenbecker; Yu-Ching Lin; Dawn T Bravo; Genevieve Clement; Adam Yagui-Beltran; M Roshni Ray; Kiyoshi Koizumi; Biao He; David M Jablons
Journal:  J Thorac Oncol       Date:  2008-10       Impact factor: 15.609

2.  p16 alterations and deletion mapping of 9p21-p22 in malignant mesothelioma.

Authors:  J Q Cheng; S C Jhanwar; W M Klein; D W Bell; W C Lee; D A Altomare; T Nobori; O I Olopade; A J Buckler; J R Testa
Journal:  Cancer Res       Date:  1994-11-01       Impact factor: 12.701

3.  The efficacy and safety of weekly vinorelbine in relapsed malignant pleural mesothelioma.

Authors:  Justin Stebbing; Thomas Powles; Kirsty McPherson; Jonathan Shamash; Paula Wells; Michael T Sheaff; Sarah Slater; Robin M Rudd; Dean Fennell; Jeremy P C Steele
Journal:  Lung Cancer       Date:  2008-05-16       Impact factor: 5.705

4.  Phase II Trial of Cediranib in Combination With Cisplatin and Pemetrexed in Chemotherapy-Naïve Patients With Unresectable Malignant Pleural Mesothelioma (SWOG S0905).

Authors:  Anne S Tsao; Jieling Miao; Ignacio I Wistuba; Nicholas J Vogelzang; John V Heymach; Frank V Fossella; Charles Lu; Mario R Velasco; Brandy Box-Noriega; James G Hueftle; Shirish Gadgeel; Mary W Redman; David R Gandara; Karen Kelly
Journal:  J Clin Oncol       Date:  2019-08-06       Impact factor: 44.544

5.  Ipilimumab and nivolumab in the treatment of recurrent malignant pleural mesothelioma (INITIATE): results of a prospective, single-arm, phase 2 trial.

Authors:  Maria J Disselhorst; Josine Quispel-Janssen; Ferry Lalezari; Kim Monkhorst; Jeltje F de Vries; Vincent van der Noort; Emmy Harms; Sjaak Burgers; Paul Baas
Journal:  Lancet Respir Med       Date:  2019-01-16       Impact factor: 30.700

6.  Nivolumab or nivolumab plus ipilimumab in patients with relapsed malignant pleural mesothelioma (IFCT-1501 MAPS2): a multicentre, open-label, randomised, non-comparative, phase 2 trial.

Authors:  Arnaud Scherpereel; Julien Mazieres; Laurent Greillier; Sylvie Lantuejoul; Pascal Dô; Olivier Bylicki; Isabelle Monnet; Romain Corre; Clarisse Audigier-Valette; Myriam Locatelli-Sanchez; Olivier Molinier; Florian Guisier; Thierry Urban; Catherine Ligeza-Poisson; David Planchard; Elodie Amour; Franck Morin; Denis Moro-Sibilot; Gérard Zalcman
Journal:  Lancet Oncol       Date:  2019-01-16       Impact factor: 41.316

7.  A conditional mouse model for malignant mesothelioma.

Authors:  Johan Jongsma; Erwin van Montfort; Marc Vooijs; John Zevenhoven; Paul Krimpenfort; Martin van der Valk; Marc van de Vijver; Anton Berns
Journal:  Cancer Cell       Date:  2008-03       Impact factor: 31.743

8.  Hsp90 stress potentiates rapid cellular adaptation through induction of aneuploidy.

Authors:  Guangbo Chen; William D Bradford; Chris W Seidel; Rong Li
Journal:  Nature       Date:  2012-01-29       Impact factor: 49.962

9.  Integrative transcriptome analysis of malignant pleural mesothelioma reveals a clinically relevant immune-based classification.

Authors:  Ania Alay; David Cordero; Sara Hijazo-Pechero; Elisabet Aliagas; Adriana Lopez-Doriga; Raúl Marín; Ramón Palmero; Roger Llatjós; Ignacio Escobar; Ricard Ramos; Susana Padrones; Víctor Moreno; Ernest Nadal; Xavier Solé
Journal:  J Immunother Cancer       Date:  2021-02       Impact factor: 13.751

10.  A Prospective Phase II Single-arm Study of Niraparib Plus Dostarlimab in Patients With Advanced Non-small-cell Lung Cancer and/or Malignant Pleural Mesothelioma, Positive for PD-L1 Expression and Germline or Somatic Mutations in the DNA Repair Genes: Rationale and Study Design.

Authors:  Francesco Passiglia; Paolo Bironzo; Luisella Righi; Angela Listì; Francesca Arizio; Silvia Novello; Marco Volante; Giorgio Vittorio Scagliotti
Journal:  Clin Lung Cancer       Date:  2020-08-05       Impact factor: 4.785
View more
  2 in total

1.  Improved Survival and Quality of Life Through an Integrative, Multidisciplinary Oncological Approach: Pathophysiological Analysis of Four Clinical Cancer Cases and Review of the Literature.

Authors:  M Berretta; A Morra; R Taibi; F Monari; N Maurea; M Ippolito; U Tirelli; F Fiorica; L Montella; G Facchini; V Quagliariello; M Montopoli
Journal:  Front Pharmacol       Date:  2022-06-16       Impact factor: 5.988

2.  Cost-effectiveness of nivolumab plus ipilimumab as first-line treatment for American patients with unresectable malignant pleural mesothelioma.

Authors:  Zhuo-Miao Ye; Zi-Qing Tang; Zhe Xu; Qin Zhou; Huan Li
Journal:  Front Public Health       Date:  2022-07-22
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.